07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Fluticasone propionate/salmeterol regulatory update

FDA accepted for review NDAs from Teva for fluticasone propionate and fluticasone propionate/salmeterol delivered via the RespiClick breath-actuated, multidose dry powder inhaler (MDPI) to treat asthma. The PDUFA dates are in 1Q17. Fluticasone propionate is...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Fluticasone propionate/salmeterol MDPI: Phase III data

Top-line data from the open-label, U.S. Phase III Study FSS-AS-305 in 1,087 adolescent and adult patients with persistent asthma showed that twice-daily 100/12.5 and 200/12.5 ug fluticasone propionate/salmeterol and twice-daily 100 and 200 ug fluticasone...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Fluticasone propionate MDPI: Phase III data

Top-line data from the double-blind, international Phase III Study FSS-AS-301 in 1,363 adolescent and adult patients with persistent asthma that was symptomatic despite low- or mid-dose inhaled corticosteroid therapy showed that twice-daily 50/12.5 and 100/12.5...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Fluticasone propionate MDPI: Phase III data

Top-line data from the double-blind, international Phase III Study FSS-AS-30017 in 1,661 adolescent and adult patients with persistent asthma that was symptomatic despite inhaled corticosteroid therapy showed that twice-daily 100/12.5 and 200/12.5 ug fluticasone propionate/salmeterol...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Fluticasone propionate MDPI: Phase III data

Top-line data from the open-label, U.S. Phase III Study FSS-AS-305 in 1,087 adolescent and adult patients with persistent asthma showed that twice-daily 100/12.5 and 200/12.5 ug fluticasone propionate/salmeterol and twice-daily 100 and 200 ug fluticasone...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Fluticasone propionate/salmeterol MDPI: Phase III data

Top-line data from the double-blind, international Phase III Study FSS-AS-30017 in 1,661 adolescent and adult patients with persistent asthma that was symptomatic despite inhaled corticosteroid therapy showed that twice-daily 100/12.5 and 200/12.5 ug fluticasone propionate/salmeterol...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Fluticasone propionate/salmeterol MDPI: Phase III data

Top-line data from the double-blind, international Phase III Study FSS-AS-301 in 1,363 adolescent and adult patients with persistent asthma that was symptomatic despite low- or mid-dose inhaled corticosteroid therapy showed that twice-daily 50/12.5 and 100/12.5...
01:56 , Nov 20, 2015 |  BC Extra  |  Clinical News

Teva's inhalers meet in Phase III asthma studies

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two multidose dry powder inhalers, fluticasone propionate/salmeterol MDPI formulation and fluticasone propionate MDPI formulation, met the primary endpoints of three Phase III trials to treat persistent asthma. The company...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Fluticasone propionate/salmeterol xinafoate: Phase III start

This month, Mylan will begin a double-blind, placebo-controlled, U.S. Phase III trial to compare bioequivalence of inhaled MGR001 vs. Advair fluticasone propionate/salmeterol administered via the Diskus multi-dose powdered inhaler from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London,...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

GlaxoSmithKline, COPD Foundation, Global Initiative for Chronic Obstructive Lung Disease (GOLD) pulmonary news

GlaxoSmithKline, GOLD and the foundation formed a new governance board to help promote and encourage uptake of the COPD Assessment Test (CAT). The partners said CAT, which was launched in 2009, is a short and...